Table 3.
Evaluation performance of all spectral parameters
| Parameters | N | AUC (95% CI) | SEN | SPE | YI | Cut-off |
|---|---|---|---|---|---|---|
| Arterial Phase | ||||||
| Zeff | 202 | 0.785 | 0.755 | 0.761 | 0.515 | 8.180 |
| IC (mg/mL) | 202 | 0.794 | 0.773 | 0.772 | 0.544 | 1.550 |
| NIC | 202 | 0.780 | 0.718 | 0.793 | 0.512 | 0.140 |
| λ HU | 202 | 0.787 | 0.736 | 0.783 | 0.519 | 1.920 |
| Venous Phase | ||||||
| Zeff | 202 | 0.808 | 0.800 | 0.761 | 0.561 | 8.190 |
| IC (mg/mL) | 202 | 0.803 | 0.791 | 0.772 | 0.563 | 1.590 |
| NIC | 202 | 0.777 | 0.709 | 0.793 | 0.503 | 0.366 |
| λ HU | 202 | 0.810 | 0.800 | 0.783 | 0.583 | 1.975 |
Zeff Z-effective, IC iodine concentration, NIC normalised iodine concentration, λ HU slope of the energy spectrum curve, AUC area under the curve, SEN sensitivity, SPE specificity, YI Youden’s index, CI confidence interval